Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department
Pallavi Ghosh1, Jesse Martinez2, Nipam Shah1
1From the Division of Pediatric Emergency Medicine, Department of Pediatrics, The University of Alabama at Birmingham Heersink School of Medicine.
Insights
Combinatorial pharmacogenomic testing shows promise in predicting medication blood levels and clinical outcomes for children with acute psychiatric crises. This approach may improve treatment efficacy by identifying gene-drug interactions.
Area of Science:
- Pharmacogenomics
- Pediatric Psychiatry
- Clinical Pharmacology
Background:
- Acute psychiatric crises in children require effective psychotropic medication management.
- Predicting individual responses to psychotropic drugs remains a challenge.
- Gene-drug interactions (GDIs) can influence medication efficacy and safety.
Purpose of the Study:
- To evaluate a combinatorial pharmacogenomic test's ability to predict medication blood levels.
- To assess the test's utility in predicting clinical improvements in pediatric patients.
- To correlate medication GDI status with treatment outcomes.
Main Methods:
- 100 pediatric patients (3-18 years) with acute psychiatric crises were enrolled.
- Combinatorial pharmacogenomic testing categorized medications as congruent or incongruent based on GDIs.
- Blood levels of specific psychotropic drugs were measured.
- Parent-rated Clinical Global Impression of Improvement (CGI-I) assessed clinical outcomes.
Main Results:
- 73% of patients were on at least one incongruent medication.
- No overall significant difference in CGI-I scores between congruent and incongruent medication groups.
- Congruent medications were associated with significantly better outcomes for depression and suicidal ideation.
- Significant associations found between GDI and blood levels for aripiprazole and escitalopram.
Conclusions:
- Pharmacogenomic testing may predict medication blood levels and outcomes in pediatric psychiatric emergencies.
- Medication congruency, identified via pharmacogenomics, shows potential for guiding treatment decisions.
- Further research is necessary to validate these preliminary findings.
Objective:
The aim of the study was to evaluate the ability of a combinatorial pharmacogenomic test to predict medication blood levels and relative clinical improvements in a selected pediatric population.
Methods:
This study enrolled patients between ages 3 to 18 years who presented to a pediatric emergency department with acute psychiatric, behavioral, or mental health crisis and/or concerns, and had previously been prescribed psychotropic medications. Patients received combinatorial pharmacogenomic testing with medications categorized according to gene-drug interactions (GDIs); medications with a GDI were considered "incongruent," and medications without a GDI were considered "congruent." Blood levels for escitalopram, fluoxetine, aripiprazole, and clonidine were evaluated according to level of GDI. Relative clinical improvements in response to the prescribed psychotropic medications were measured using a parent-rated Clinical Global Impression of Improvement (CGI-I) assessment, where lower scores corresponded with greater improvement.
Results:
Of the 100 patients enrolled, 73% reported taking ≥1 incongruent medication. There was no significant difference in CGI-I scores between patients prescribed congruent versus incongruent medications (3.37 vs 3.68, P = 0.343). Among patients who presented for depression or suicidal ideation, those prescribed congruent medications had significantly lower CGI-I scores compared with those taking incongruent medications ( P = 0.036 for depression, P = 0.018 for suicidal ideation). There was a significant association between medication GDI and blood levels for aripiprazole (n = 15, P = 0.01) and escitalopram (n = 10, P = 0.01).
Conclusions:
Our preliminary findings suggest that combinatorial pharmacogenomic testing can predict medication blood levels and relative outcomes based on medication congruency in children presenting to an emergency department with acute psychiatric/behavioral crises. Additional studies will be needed to confirm these findings.
More Related Videos
07:31Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
Related Concept Videos
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
01:21Factors Affecting Drug Response: Overview
01:28Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
01:12Analysis of Population Pharmacokinetic Data
01:26Psychosis: Goals of Pharmacotherapy
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...